SYSTEMATIC REVIEW article

Front. Surg., 20 September 2022

Sec. Genitourinary Surgery and Interventions

Volume 9 - 2022 | https://doi.org/10.3389/fsurg.2022.986679

The diagnostic value of non-invasive methods for diagnosing bladder outlet obstruction in men with lower urinary tract symptoms: A meta-analysis

  • Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Article metrics

View details

10

Citations

2,9k

Views

1k

Downloads

Abstract

Purpose:

We conducted the first meta-analysis to determine the diagnostic value of non-invasive methods for diagnosing bladder outlet obstruction (BOO) in men with lower urinary tract symptoms (LUTS).

Methods:

We searched a range of databases for relevant publications up to June 2022, including PubMed, Embase, Web of Science, and the Cochrane Library. Retrieved studies were then reviewed for eligibility and data were extracted. The risk of bias (RoB) was assessed using the QUADAS-2 tool. We then performed a formal meta-analysis to evaluate the accuracy of various non-invasive methods for diagnosing BOO in men.

Results:

We identified 51 eligible studies including 7,897 patients for meta-analysis. The majority of the studies had a low overall RoB. Detrusor wall thickness (DWT) (pooled sensitivity (SSY): 71%; specificity (SPY): 88%; diagnostic odds ratio (DOR): 17.15; area under curve (AUC) 0.87) and the penile cuff test (PCT) (pooled SSY: 87%; SPY: 78%; DOR: 23.54; AUC: 0.88) showed high accuracy for diagnosing BOO. Furthermore, data suggested that DWT had the highest pooled SPY (0.89), DOR (32.58), and AUC (0.90), when using 2 mm as the cut-off.

Conclusion:

Of the non-invasive tests tested, DWT and PCT had the highest levels of diagnostic accuracy for diagnosing BOO in men with LUTS. DWT, with a 2 mm cut-off, had the highest level of accuracy. These two methods represent good options as non-invasive tools for evaluating BOO in males.

Introduction

Lower urinary tract symptoms (LUTS) can be very troublesome for both male and female patients and can cause a reduction in their quality of life. Most patients seek medical help due to bothersome LUTS, especially when they develop bladder outlet obstruction (BOO) as this can result in severe urinary difficulty (1). BOO is mainly caused by benign prostatic hyperplasia (BPH) and usually requires surgical treatment. Therefore, it is very important that we can determine whether LUTS is due to BOO if we are to optimize patient management (2). Over recent years, the evaluation of LUTS/BPH has depended heavily on pressure-flow study (PFS) of urodynamic study (UDS) as the gold standard diagnostic tests for BOO (3). However, UDS has several disadvantages. First, PFS requires transurethral intubation and may cause urinary symptoms, such as hematuria and urinary tract infections. Furthermore, PFS can be unpleasant and is commonly associated with anxiety and embarrassment (4). In addition, UDS is expensive, time consuming, and requires delicate instruments and specific expertise.

Given the invasive nature and side effects associated with conventional invasive PFS, a variety of non-invasive diagnostic methods have been developed (5). Although these novel and non-invasive diagnostic methods were designed to improve the quality of life in patients with LUTS by promoting earlier diagnosis and treatment, and do show significant potential (6), there is some conflict with regards to their specific clinical outcomes. Previous authors have evaluated and summarized the diagnostic value of these non-invasive methods (5, 714); nevertheless, researchers have yet to perform a meta-analysis to investigate the diagnostic accuracy for these approaches in a quantitative manner.

The aim of the present meta-analysis was to re-evaluate and determine the diagnostic accuracy of non-invasive methods for the diagnosis of BOO in men with LUTS by assessing sensitivity (SSY), specificity (SPY), diagnostic odds ratio (DOR) and area under curve (AUC). This was the first meta-analysis to quantitatively compare the diagnostic value of different non-invasive methods for BOO.

Materials and methods

This meta-analysis was conducted based on Preferred Reporting Items for a Systematic Review and Meta-Analysis (PRISMA). Neither ethical approval or informed consent was required for this study.

Search strategy

We searched a range of databases for relevant publications up to June 2022, including PubMed, Embase, Web of Science, and the Cochrane Library. The search strategy was (“uroflowmetry” OR “flow rate” OR “intravesical prostat* protrusion” OR “intravesical protrusion” OR “penile cuff” OR “urocuff” OR “detrusor wall thickness” OR “detrusor thickness” OR “bladder wall thickness” OR “bladder thickness” OR “external condom catheter” OR “doppler ultrasound” OR “resistive index” OR “velocity ratio” OR “bladder weight” OR “prostate volume” OR “international prostat* symptom* score” OR “IPSS” OR “residual urine” OR “post-void* residual urine” OR “RUV” OR “PVR” OR “prostat* specific antigen” OR “PSA” OR “near-infrared spectroscopy” OR “noninvasive” OR “non-invasive” OR “noninvasively” OR “non-invasively”) AND (“bladder obstruction” OR “benign prostatic obstruction” OR “bladder outlet obstruction” OR “bladder outflow obstruction” OR “BOO” OR “BPO” OR “infravesical obstruction”). To achieve a comprehensive literature search, we also reviewed the reference lists of the retrieved literature. The articles included in this study were restricted to human subjects and those published in English. Two researchers carried out the same literature screening protocols; any disagreements were resolved by a third researcher.

Eligibility criteria

Following the removal of duplicate articles, two researchers independently reviewed the titles and abstracts of the retrieved studies. To be eligible for analysis, the articles needed to meet our specific inclusion criteria: (1) population: patients with LUTS aged ≥18 years; (2) index test: non-invasive methods. The following noninvasive tests were eligible for inclusion in meta-analysis: the penile cuff test (PCT), near-infrared spectrum (NIRS), ultrasonography of post-voided residual (PVR), intravesical prostatic protrusion (IPP), detrusor wall thickness (DWT), bladder wall thickness (BWT), resistive index (RI), prostate volume (PV), and free uroflowmetry, a detailed description of each index test is included in the Supplementary Material; (3) reference standard: invasive PFS; (4) outcome: diagnostic accuracy for the diagnosis of BOO; (5) study design: any type, including comparative studies, clinical trials, retrospective or prospective studies; (6) complete data: all data could be obtained directly or calculated and included true positive (TP), false positive (FP), true negative (TN), and false negative (FN) data. The exclusion criteria were as follows: (1) failure to meet the inclusion criteria; (2) duplicated publications; (3) reviews, case reports, conference abstracts, letters and editorials; (4) non-English and non-human studies.

Data extraction

All data extraction was completed by two researchers independently and manually according to the inclusion criteria, any inconsistency was resolved by a third researcher. We extracted a range of data from eligible publications, including: (a) author-year; (b) study design; (c) mean age; (d) country; (e) sample size; (f) index test; (g) cut-off value; (h) TP; (i) FP; (j) TN; and (k) FN.

Quality assessment

The quality of all studies included in this meta-analysis was assessed by two researchers in accordance with the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool (15). This tool was used to evaluate the risk of bias (RoB) on the basis of the following criteria: patient selection, index test, reference standard, flow and timing, and assessing applicability concerns by patient selection, index test, reference test.

Statistical analysis

To determine the diagnostic accuracy of non-invasive tests for the diagnosis of BOO, we adopted pooled SSY, SPY, DOR and AUC of summary receiver operating characteristics (SROC) as the primary indicators. Because these four indicators can well illustrate the diagnostic ability of the index tests (1618). The SSY represents the ability to detect disease and the SPY represents the ability to exclude a disease. The DOR is a measure for the discriminative power of a diagnostic test: the ratio of the odds of a positive test result among diseased to the odds of a positive test result among the non-diseased. SROC curves are used to determine test performances and present the tradeoff between the SSY and SPY of non-invasive tests. A two-by-two contingency table (consisting of TP, FP, FN and TN) was then constructed based on the data extracted from each study included in the meta-analysis. If a study used different cut-off values for the same index test, we adopted data for the most common cut-off value to conduct the meta-analysis. A bivariate model was then used to calculate the pooled SSY, SPY, DOR and AUC, along with 95% confidence intervals (CIs) (19). Pooled data was displayed using forest plots and summary receiver operating characteristics (SROC) plots. The heterogeneity of the pooled data was assessed by Cochrane's Q test and I2 test (20). If the data showed little heterogeneity (P ≥ 0.1 and I2 < 50%), a fixed-effect model was used; otherwise, a random-effect model was adopted. A threshold effect was determined by calculating Spearman's correlation coefficient between SSY and the false positive rate (1-SPY) (18); a strong positive correlation was considered a significant threshold effect. Sensitivity analysis and meta-regression were also conducted to explore the sources of heterogeneity relating to non-threshold effects. Publication bias was evaluated with Deeks’ funnel plots and an associated regression test of asymmetry (21). Data were analyzed by STATA version 14.0 (StataCorp LP, College Station, TX, USA) using midas commands. Spearman's correlation coefficient was calculated by MetaDiSc 1.4 (Universidad Complutense, Madrid, Spain). Quality assessment was performed by RevMan 5.3 (Cochrane Collaboration, Oxford, UK). P < 0.05 was considered statistically significant.

Results

Literature searches and study characteristics

We conducted a comprehensive literature search of the PubMed, Embase, Web of Science and the Cochrane Library databases following an established search strategy. We identified a total of 10,058 articles. After the removal of duplicates, reviews, case reports, conference abstracts, letters, and editorials, 2,937 articles were left for screening. Then, 2,886 studies were removed following abstract and full-text evaluation and by insufficient data. For BWT, one study resulted in a significant increase in heterogeneity, after excluding this study, the final number of studies was not enough to perform meta-analysis. For NIRS, the method and calculation in each of the study was different from the other and far from being standard, Therefore, we did not include these two index tests. Finally, 51 articles were eligible for meta-analysis (2272). Full details of the screening process are shown in Figure 1.

Figure 1

Of the 51 studies included in this meta-analysis, the publication year ranged from 1994 to 2021. These studies involved 21 countries and a total of 7,897 participants. All of the 51 studies were non-randomized trials (NRT); 22 studies were prospective, two were retrospective; 14 studies were blinded, 13 were not blinded; and the remaining studies did not describe their specific design. All 51 studies examined the accuracy of non-invasive methods for the diagnosis of BOO in men with LUTS, using PFS as the gold standard. For specific descriptions of the included studies, see Table 1.

Table 1

Author-yearCountryStudy designPatients numberAge (mean)Index testCut-offTPFPFNTN
Poulsen 1994 (22)DenmarkNR, NRT, No15368Qmax10 ml/s68233131
153Qmax15 ml/s89371017
Comiter 1996 (23)AmericanNR, NRT, NR20568.3Qmax12 ml/s80272375
Reynard 1996 (24)EnglandNR, NRT, No165NRQmax8 ml/s43105756
165Qmax10 ml/s71192946
165Qmax12 ml/s83331633
165Qmax15 ml/s9542523
Ding 1997 (25)SingaporePS, NRT, NR12675PVR50 ml17303148
DuBeau 1998 (26)AmericanNR, NRT, No9972.4PVR50 ml6019713
99PVR100 ml53181414
99PVR200 ml47142018
99Qmax10 ml3793023
Reynard 1998 (27)EnglandNR, NRT, No89766.5Qmax10 ml/s252107288250
897Qmax15 ml/s440221100136
Kuo 1999 (28)Tai wanPS, NRT, No32467.2PV20 ml1043310879
324PV40 ml352177110
324PVR50 ml379175103
324PVR100 ml315181107
324Qmax10 ml/s135447768
324Qmax15 ml/s179753337
Rasmussen 1999 (29)DenmarkNR, NRT, NR2966PVR50 ml021512
29Qmax10 ml/s501014
29Qmax15 ml/s9866
Kojima 2000 (30)JapanNR, NRT, NR57NRRI0.72813511
Steele 2000 (31)AmericanPS, NRT, NR20466.7PV40 ml100195233
204Qmax10 ml/s111214131
Sullivan 2000 (32)AmericanNR, NRT, No90NRPCTPCR index 100%3917440
Oelke 2002 (33)GermanyNR, NRT, NR7063DWT2 mm2111236
70PV20 ml3027310
70PVR50 ml2721616
70Qmax15 ml/s3327010
Watanabe 2002 (34)JapanPS, NRT, No5166.4PV30 ml + H:W 0.81001427
Blenky 2003 (35)IsraelPS, NRT, Yes2965.6RI0.719136
Chia 2003 (36)SingaporePS, NRT, Yes20064.6IPP10 mm9563069
200IPP5 mm11641934
200PV30 ml99342641
200PVR100 ml9373268
200Qmax10 ml/s113391236
Salinas 2003 (37)SpainNR, NRT, Yes5254.1PCTnomogram348010
Aganovic 2004 (38)B/HNR, NRT, NR10264.68Qmax10 ml/s4733022
Harding 2004 (39)EnglandNR, NRT, Yes10163PCTPCR index 160%2511758
101Qmax10 ml/s2625644
Griffiths 2005 (40)EnglandNR, NRT, No144NRPCTGriffiths nomogram36172071
Nose 2005 (41)JapanNR, NRT, Yes3062.5IPP10 mm98112
Kessler 2006 (42)SwitzerlandNR, NRT, No10267DWT1.5 mm613506
102DWT2 mm5613528
102DWT2.5 mm4351936
102DWT2.9 mm2603541
Lim 2006 (43)SingaporePS, NRT, NR9566IPP5 mm4025723
95IPP10 mm2292539
95PV20 ml4336412
95PV40 ml24122336
Oelke 2007 (44)NetherlandPS, NRT, Yes16062DWT2 mm6841381
160PV25 ml64621123
160PVR50 ml54492136
160Qmax10 ml/s51232462
160Qmax15 ml/s7452133
Reis 2008 (45)BrazilPS, NRT, Yes4264.8IPP5 mm1911111
42IPP10 mm167415
Ku 2009 (46)KoreaNR, NRT, No21267.5PV35 ml47661089
212PV40 ml425415101
212PV45 ml374120114
212Qmax10 ml/s335324102
212Qmax12 ml/s44711384
212Qmax15 ml/s54112343
Franco 2010 (47)ItalyPS, NRT, Yes10067DWT6 mm5452021
100IPP12 mm4862620
100PV38 ml53102116
Abdel-Aal 2011 (48)EgyptNR, NRT, Yes8558.7DWT2 mm23121238
85IPP8 mm2810740
85PV45 ml3037513
Pascual 2011 (49)SpainPS, NRT, No3963.1IPP10.5 mm195213
Aganovic (a) 2012 (50)B/HNR, NRT, NR11165.4IPP10 mm32112246
Aganovic (b) 2012 (51)B/HPS, NRT, NR11065.3IPP12 mm3792539
Aldaqadossi 2012 (52)EgyptPS, NRT, Yes33865RI0.711343924141
Hossain 2012 (53)BangladeshNR, NRT, NR5064.3IPP10 mm185819
50PV40 ml1581116
Zhang 2012 (54)ChinaPS, NRT, Yes7469.9RI0.694031120
Elsaied 2013 (55)EgyptNR, NRT, Yes5061.7DWT2 mm192425
50PV25 ml201938
50PVR50 ml1715612
50Qmax10 ml/s2317010
Shin 2013 (56)KoreaRS, NRT, NR23969.9IPP5.5 mm313815155
239PV30 ml308016113
239PVR50 ml232023173
239Qmax10 ml/s37100993
Bianchi 2014 (57)ItalyNR, NRT, No4861.5PCTGriffiths nomogram2110017
Zhang 2014 (58)ChinaPS, NRT, Yes5565.7PV54.4 ml41725
Kazemeyni 2015 (59)IranNR, NRT, NR5165.5PCTGriffiths nomogram168225
Matulewicz 2015 (60)AmericanNR, NRT, No19NRPCTModified ICS nomogram12142
Ahmed 2016 (61)ArabiaPS, NRT, NR15765IPP10.9 mm8762242
Lee 2016 (62)SingaporeNR, NRT, NR6166IPP5 mm1427020
61IPP10 mm811636
Suzuki 2016 (63)JapanRS, NRT, NR35068.9IPP10 mm1354245128
350PV40.1 ml1095071120
350RI0.7261246856102
Farag 2017 (64)EgyptNR, NRT, NR7263.0Qmax7 ml/s3112416
Ko 2017 (65)KoreaPS, NRT, Yes10767PCTGriffiths nomogram2622356
Aganovic 2019 (66)B/HPS, NRT, NR13566.1PCTPCR index 96.4%5241861
Garg 2019 (67)IndiaPS, NRT, NR24057.1DWT5.5 mm8048868
240IPP7.5 mm146122260
240RI0.62132123660
Reddy 2019 (68)IndiaPS, NRT, NR16466.72IPP5 mm8340833
164IPP10 mm54113762
Kim 2020 (69)KoreaNR, NRT, NR5969.6PCTModified ICS nomogram360914
Mosawi, 2020 (70)NRNR, NRT, NR63NRIPP10 mm3115710
63PV40 ml21151710
Park, 2020 (71)KoreaPS, NRT, NR19669.5DWT3 mm36294883
Wadie, 2021 (72)EgyptPS, NRT, NR45954PV40 ml1057275193
459Qmax10 ml/s15013413540
459Qmax15 ml/s3966246108

Characteristics of the included studies.

TP, true positive; FP, false positive; FN, false negative; TN, true negative; NRT, non-randomized trial; PS, prospective study; RS, retrospective study; No, not blinded; Yes, blinded; NR, not referred; Qmax, maximum flow rate; PVR, post-voided residual; PV, prostate volume; RI, resistive index; PCT, penile cuff test; IPP, intravesical prostatic protrusion; DWT, detrusor wall thickness; B/H, Bosnia and Herzegovina.

Quality assessment

Outcomes relating to quality assessment and RoB are shown in Figure 2. Overall, the RoB was generally low for most studies. In the patient selection domain, three studies were classified as high risk due to inappropriate inclusion or exclusion criteria. Twenty-three studies had an unclear risk because it was unknown as to whether they adopted consecutive patients or random samples. In the index test domain, 6 studies showed high risk because the results of the index test were interpreted with knowledge of the reference standard. Nine studies were associated with an unclear risk. In the reference standard domain, 12 studies had a high risk due to knowledge of the results of index tests when interpreting the results of the reference standard; the other 20 studies were at an unclear risk. In the flow and timing domain, only two studies had a high risk; this was due to an inappropriate interval between the index test and the reference standard. In terms of applicability concern, the majority of the publications were at low risk, thus indicating that the patients, index test, and reference standard, for most studies were representative of clinical routine practice.

Figure 2

Quantitative analysis of the results (meta-analysis)

With regards to the index tests (DWT, PCT, RI, IPP, Qmax, PV, PVR), we conducted quantitative analysis (meta-analysis) for these tests. The data extracted or calculated from published studies are presented in Table 1.

Diagnostic accuracy results

Outcomes for pooled SSY, SPY, DOR, and AUC of SROC curve are shown in Figures 35. Figure 3 shows the pooled SSY and SPY. Across these tests, the pooled SSY ranged from 71% to 87% and the pooled SPY ranged from 74% to 88%. PCT had the highest pooled SSY at 87% (95% CI: 77%–93%) (Figure 3B), followed by RI at 79% (95% CI: 73%–84%) (Figure 3C). DWT had the highest pooled SPY at 88% (95% CI: 78%–93%) (Figure 3A), followed by IPP at 79% (95% CI: 74%–83%) (Figure 3D). The pooled DOR, as presented by forest plots, are shown in Figure 4, ranging from 9.94 to 23.54. PCT exhibited the optimal DOR (23.54, 95% CI: 13.56–40.85) (Figure 4B), followed by DWT at 17.15 (95% CI: 7.09–41.46) (Figure 4A). Due to a significant threshold effect was found for PCT, Qmax and PV, thus we only fit SROC curve and calculate the area under ROC curve for these three tests. SROC curves indicated that DWT and PCT had a relatively better diagnostic power, with AUCs of 0.87 (95% CI: 0.84–0.90) and 0.88 (95% CI: 0.85–0.91) respectively. These indicators are summarized in Table 2. In brief, DWT and PCT showed high levels of diagnostic accuracy; the pooled SSY and SPY exceeded 70%, DORs were the highest and the pooled AUCs exceeded 0.85.

Figure 3

Figure 4

Figure 5

Table 2

TestnPatientsSSY (95% CI)SPY (95% CI)DOR (95% CI)AUC (95% CI)
DWT81,0030.71 (0.57, 0.82)0.88 (0.78, 0.93)17.15 (7.09, 41.46)0.87 (0.84, 0.90)
PCT108060.87 (0.77, 0.93)0.78 (0.70, 0.84)23.54 (13.56, 40.85)0.88 (0.85, 0.91)
RI61,0880.79 (0.73, 0.84)0.74 (0.62, 0.83)10.74 (5.04, 22.89)0.83 (0.80, 0.86)
IPP172,1360.73 (0.67, 0.78)0.79 (0.74, 0.83)9.94 (6.94, 12.24)0.83 (0.79, 0.86)
Qmax193,911---0.74 (0.70, 0.78)
PV172,767---0.70 (0.66, 0.74)
PVR91,297---0.69 (0.65, 0.73)

Summary of the pooled data for each type of the index test.

SSY, sensitivity; SPY, specificity; DOR, diagnostic odds ratio; AUC, area under curve; PLR, positive likelihood ratio; NLR, negative likelihood ratio; DS, diagnostic score; DWT, detrusor wall thickness; PCT, penile cuff test; RI, resistive index; IPP, intravesical prostatic protrusion; Qmax, maximum flow rate; PV, prostate volume; PVR, post-voided residual.

The diagnostic accuracy of each type of test using the most commonly used cut-off

We selected the most commonly used threshold values for each test to perform further analysis. We found that DWT (using 2 mm as the cut-off) possessed the greatest diagnostic accuracy for diagnosing BOO in men across these index tests, with a pooled SSY of 0.79 (95% CI: 0.68–0.88), SPY of 0.89 (95% CI: 0.75–0.96), DOR of 32.58 (95% CI: 12.04–88.17), and an AUC of 0.90 (95% CI: 0.87–0.92). PCT (using Griffith's nomogram as the diagnostic criteria) had the second-best diagnostic accuracy, with a pooled SSY of 0.89 (95% CI: 0.67–0.97), SPY of 0.73 (95% CI: 0.65–0.81), DOR of 22.98 (95% CI: 6.76–77.76) and an AUC of 0.81 (95% CI: 0.78–0.85). Table 3 shows a summary of results for each type of index test using the most commonly threshold values.

Table 3

TestnCut-offSSY (95% CI)SPY (95% CI)DOR (95% CI)AUC (95% CI)
DWT52 mm0.79 (0.68, 0.88)0.89 (0.75, 0.96)32.58 (12.04, 88.17)0.90 (0.87, 0.92)
PCT4Griffiths nomogram0.89 (0.67, 0.97)0.73 (0.65, 0.81)22.98 (6.76, 77.76)0.81 (0.78, 0.85)
IPP1010 mm0.70 (0.62, 0.77)0.77 (0.68, 0.84)7.67 (4.89, 12.01)0.79 (0.75, 0.83)
Qmax1510 ml/s0.69 (0.59, 0.77)0.63 (0.52, 0.72)3.65 (2.30, 5.79)0.70 (0.66, 0.74)
PV740 ml0.54 (0.40, 0.68)0.76 (0.57, 0.88)3.74 (2.59, 5.42)0.68 (0.64, 0.72)
PVR850 ml0.53 (0.28, 0.77)0.68 (0.47, 0.84)2.45 (1.30, 4.64)0.66 (0.61, 0.70)

Summary of the pooled data for each type of index test using the most commonly used threshold values.

SSY, sensitivity; SPY, specificity; DOR, diagnostic odds ratio; AUC, area under curve; PLR, positive likelihood ratio; NLR, negative likelihood ratio; DS, diagnostic score; DWT, detrusor wall thickness; PCT, penile cuff test; IPP, intravesical prostatic protrusion; Qmax, maximum flow rate; PV, prostate volume; PVR, post-voided residual.

Heterogeneity test

The heterogeneity between studies included threshold effects and non-threshold effects. The threshold effect was assessed by Spearman's correlation coefficient, with values of 0.119 (P = 0.779) for DWT, 0.673 (P = 0.033) for PCT, 0.029 (P = 0.957) for RI, 0.383 (P = 0.129) for IPP, 0.527 (P = 0.025) for Qmax, 0.813 (P = 0.000) for PV, and 0.583 (P = 0.099) for PVR. Therefore, a statistically significant threshold effect was found for PCT, Qmax and PV and we only fit SROC curve and calculate the area under ROC curve for these three tests (Figures 5E–G; Table 2). The heterogeneity of the non-threshold effect was assessed by Cochrane's Q test and I2 test. Forest plots showed that the heterogeneity for the pooled SSY, SPY and DOR for all of these index tests were generally high (P < 0.1 for Cochrane's Q test and I2 > 50% for I2 test). Therefore, a random effect model was applied when pooling the data. To investigate the potential sources of heterogeneity, we conducted sensitivity analysis and meta-regression analysis.

Sensitivity analysis

We conducted sensitivity analysis to evaluate the effect of each individual study on the pooled DOR by removing the eligible study one by one for each of the index tests. The pooled data was not changed substantially by removing any of the eligible studies for these index tests (Figure 6).

Figure 6

Meta-regression

Next, we performed meta-regression analysis to further identify the sources of heterogeneity, including publication year (pre-2010 vs. post-2010), mean age (≤65 vs. >65), sample size (≤100 vs. >100) and cut-off (most common vs. not). The results of meta-regression analysis are presented in Figure 7. Analysis indicated that some of these four factors may represent the source of heterogeneity for these index tests and that the origin of heterogeneity would be different for different tests.

Figure 7

Publication bias

Finally, publication bias was evaluated with a Deeks’ funnel plot and an associated regression test for asymmetry. Funnel plots showed that studies relating to DWT, PCT, RI, IPP, PV and PVR were all evenly distributed on both sides of the regression line (P > 0.05; Figure 8). A significant publication bias was identified for studies involving Qmax (P < 0.05).

Figure 8

Discussion

There are several limitations to the use of UDS to diagnose BOO in men, including the invasive nature of this technique, high costs, and side effects. Consequently, there is significant interest in the development of non-invasive methods to diagnose BOO. Over recent years, several different methods have been developed. However, no meta-analysis has been performed to evaluate the diagnostic accuracy of these new non-invasive tests for diagnosing BOO in men. Therefore, we conducted the first meta-analysis to investigate the diagnostic accuracy of seven non-invasive tests by pooling the data and performing quantitative analysis.

Previous studies have investigated the accuracy of non-invasive tools for the diagnosis of BOO in men; however, conclusions remain inconsistent. A previous systematic review reported that PCT, DWT and NIRS had the highest median SSYs ranging from 82% to 85.7% (5). The highest median NPVs ranged from 84% to 89% when using the most common cut-offs. The findings of our present meta-analysis are consistent with these earlier findings in that systematic review-DWT and PCT were the two most promising non-invasive tests.

Our results indicated that the pooled DORs for DWT and PCT were 17.15 (95% CI: 7.09–41.46) and 23.54 (95% CI: 13.56–40.85) respectively. Furthermore, DWT (using 2 mm as the cut-off) exhibited the highest DOR value (32.58, 95% CI: 12.04–88.17). The DOR is one of the most primary indicators for test accuracy and combines data from SSY and SPY into a single number (73). These data suggested that DWT and PCT had the highest accuracies for the diagnosis of BOO in men when compared among the seven non-invasive methods, especially with DWT using the most commonly used cut-off. Furthermore, the SPY (0.89, 95% CI: 0.75–0.96) and AUC (0.90, 95% CI: 0.87–0.92) values for DWT were also the highest. Unlike a conventional ROC curve, which observes the effect of varying cut-offs on SSY and SPY in a single study, each data point represents an individual study in a SROC curve (18). Our results showed that DWT and PCT had a relatively better diagnostic power, with AUCs of 0.87 (95% CI: 0.84–0.90) and 0.88 (95% CI: 0.85–0.91) respectively.

A vital aspect of meta-analysis is to identify the sources of heterogeneity (74). In the present study, heterogeneity tests showed that PCT, Qmax, and PV, had a significant threshold effect. The heterogeneity of the pooled data caused by non-threshold effects was generally high. We did not find that any single study had a significant influence on the pooled data for each type of non-invasive method. However, in our meta-regression analysis, we found that publication year had a significant influence on the SSY of DWT, RI and the SSY of IPP. The mean age exerted an effect on the SSY of IPP, Qmax, PV and PVR. Sample size had an effect on the SSY of PCT, RI, IPP, and the SPY of IPP. The cut-off exerted impact on the SSY of RI, IPP, PV and the SPY of PCT and IPP, thus indicating that researchers need to unify the publication year, mean age, sample size, and/or cut-offs for the corresponding tests affected by these factors in future studies. In addition to this, although the risk of bias was generally low across most domains in most of the studies included in the present analysis, it is worth noting that all of the included studies were non-randomized trials. Only 14 studies applied the blinding methods, the remaining studies were unblinded or unknown. Furthermore, some studies adopted varying thresholds for the same index test and several studies applied different standards to define BOO in men. Therefore, blinding, study design, and the definitions used for BOO may also cause bias in the pooled data.

This was the first meta-analysis to explore the accuracy of non-invasive methods for diagnosing BOO in men. We performed a more comprehensive literature search to provide a newer and more complete dataset so that we could perform quantitative analysis. Nevertheless, there were several limitations. Firstly, we generally observed high levels of heterogeneity in the included studies for each type of index test. Secondly, all of the included studies were non-randomized trials, some were retrospective or were unblinded; this may have induced bias. Thirdly, some of the included studies adopted varying cut-offs or definitions for BOO, this may cause bias. Finally, only studies that were written in English were included; whether studies in other languages could have influenced our results remains unknown.

Conclusion

This meta-analysis provided relatively good evidence for the diagnostic accuracy of some non-invasive tests, this evidence is not sufficient to provide a new gold standard. However, larger studies, with more stringent methodological standards and larger sample sizes, are now required to better evaluate their value in the diagnosis of BOO in men with LUTS. Of the non-invasive tests tested, DWT and PCT had the highest levels of diagnostic accuracy for diagnosing BOO in men with LUTS. DWT, with a 2 mm cut-off, had the highest level of accuracy. These two methods represent good options as non-invasive tools for evaluating BOO in males.

Statements

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

Author contributions

SX and YC performed the experiment and wrote the paper. TL, XW, QL, KR, XY, ZC and GD performed the research and analyzed data. All authors contributed to the article and approved the submitted version.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer MX declared a shared affiliation, with no collaboration, with the authors at the time of review.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fsurg.2022.986679/full#supplementary-material.

References

  • 1.

    HutchisonAFarmerRChappleCBergesRPientkaLTeillacPet alCharacteristics of patients presenting with LUTS/BPH in six European countries. Eur Urol. (2006) 50:55561. 10.1016/j.eururo.2006.05.001

  • 2.

    RadomskiSBHerschornSNaglieG. Acute urinary retention in men: a comparison of voiding and nonvoiding patients after prostatectomy. J Urol. (1995) 153:6858. 10.1016/S0022-5347(01)67686-9

  • 3.

    NittiVW. Pressure flow urodynamic studies: the gold standard for diagnosing bladder outlet obstruction. Rev Urol. (2005) 7(Suppl 6):S1421. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1477621/pdf/riu007006_S014.pdf

  • 4.

    ShawCWilliamsKAssassaPRJacksonC. Patient satisfaction with urodynamics: a qualitative study. J Adv Nurs. (2000) 32:135663. 10.1046/j.1365-2648.2000.01627

  • 5.

    MaldeSNambiarAKUmbachRLamTBBachTBachmannAet alEuropean association of urology non-neurogenic male LUTS guidelines panel. Systematic review of the performance of noninvasive tests in diagnosing bladder outlet obstruction in men with lower urinary tract symptoms. Eur Urol. (2017) 71:391402. 10.1016/j.eururo.2016.09.026

  • 6.

    SwavelyNRSpeichJEStothersLKlausnerAP. New diagnostics for male lower urinary tract symptoms. Curr Bladder Dysfunct Rep. (2019) 14:907. 10.1007/s11884-019-00511-0

  • 7.

    BelalMAbramsP. Noninvasive methods of diagnosing bladder outlet obstruction in men. Part 1: nonurodynamic approach. J Urol. (2006) 176:228. 10.1016/S0022-5347(06)00569-6

  • 8.

    BelalMAbramsP. Noninvasive methods of diagnosing bladder outlet obstruction in men. Part 2: noninvasive urodynamics and combination of measures. J Urol. (2006) 176:2935. 10.1016/S0022-5347(06)00570-2

  • 9.

    GriffithsCJPickardRS. Review of invasive urodynamics and progress towards non-invasive measurements in the assessment of bladder outlet obstruction. Indian J Urol. (2009) 25:8391. 10.4103/0970-1591.45544

  • 10.

    MangeraAChappleC. Modern evaluation of lower urinary tract symptoms in 2014. Curr Opin Urol. (2014) 24:1520. 10.1097/MOU.0000000000000013

  • 11.

    MangeraAOsmanNIChappleCR. Assessment of BPH/BOO. Indian J Urol. (2014) 30(2):17780. 10.4103/0970-1591.126902

  • 12.

    ParsonsBABrightEShabanAMWhitehouseADrakeMJ. The role of invasive and non-invasive urodynamics in male voiding lower urinary tract symptoms. World J Urol. (2011) 29:1917. 10.1007/s00345-009-0488-8

  • 13.

    PickardRGriffithsC. Noninvasive methods of diagnosing bladder outlet obstruction. Indian J Urol. (2009) 25:812. 10.4103/0970-1591.45543

  • 14.

    SahaiASethJAaFVDPanickerJRidderDDasguptaP. Current state of the art in non-invasive urodynamics. Curr Bladder Dysfunct Rep. (2013) 8:8391. 10.1007/s11884-013-0181-z

  • 15.

    WhitingPFRutjesAWWestwoodMEMallettSDeeksJJReitsmaJBet alQUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. (2011) 155:52936. 10.7326/0003-4819-155-8-201110180-00009

  • 16.

    IrwigLTostesonANGatsonisCLauJColditzGChalmersTCet alGuidelines for meta-analyses evaluating diagnostic tests. Ann Intern Med. (1994) 120:66776. 10.7326/0003-4819-120-8-199404150-00008

  • 17.

    MosesLEShapiroDLittenbergB. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med. (1993) 12:1293316. 10.1002/sim.4780121403

  • 18.

    DevilléWLBuntinxFBouterLMMontoriVMde VetHCvan der WindtDAet alConducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol. (2002) 2:9. 10.1186/1471-2288-2-9

  • 19.

    ReitsmaJBGlasASRutjesAWScholtenRJBossuytPMZwindermanAH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol. (2005) 58:98290. 10.1016/j.jclinepi.2005.02.022

  • 20.

    HigginsJPThompsonSGDeeksJJAltmanDG. Measuring inconsistency in meta-analyses. Br Med J. (2003) 327:557. 10.1136/bmj.327.7414.557

  • 21.

    DeeksJJMacaskillPIrwigL. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. (2005) 58:88293. 10.1016/j.jclinepi.2005.01.016

  • 22.

    PoulsenALSchouJPuggaardLTorp-PedersenSNordlingJ. Prostatic enlargement, symptomatology and pressure/flow evaluation: interrelations in patients with symptomatic BPH. Scand J Urol Nephrol Suppl. (1994) 157:6773. https://www.scopus.com/record/display.uri?eid=2-s2.0-0028183089/origin=inward

  • 23.

    ComiterCVSullivanMPSchacterleRSYallaSV. Prediction of prostatic obstruction with a combination of isometric detrusor contraction pressure and maximum urinary flow rate. Urology. (1996) 48:7239. 10.1016/S0090-4295(96)00420-7

  • 24.

    ValentiniFANelsonPPBessonGRZimmernPE. Challenging the maximum flow rate: a new index of voiding dysfunction in men with benign prostatic enlargement. BJU Int. (2008) 101:9959. 10.1111/j.1464-410X.2008.07460.x

  • 25.

    DingYYLieuPKChooPW. Is the bladder “an unreliable witness” in elderly males with persistent lower urinary tract symptoms?Geriatr Nephrol Urol. (1997) 7:1721. 10.1023/a:1008299528728

  • 26.

    DuBeauCEYallaSVResnickNM. Improving the utility of urine flow rate to exclude outlet obstruction in men with voiding symptoms. J Am Geriatr Soc. (1998) 46:111824. 10.1111/j.1532-5415.1998.tb06650.x

  • 27.

    ReynardJMYangQDonovanJLPetersTJSchaferWRosetteJJet alThe ICS-'BPH’ study: uroflowmetry, lower urinary tract symptoms and bladder outlet obstruction. Br J Urol. (1998) 82:61923. 10.1046/j.1464-410x.1998.00813.x

  • 28.

    KuoHC. Clinical prostate score for diagnosis of bladder outlet obstruction by prostate measurements and uroflowmetry. Urology. (1999) 54:906. 10.1016/s0090-4295(99)00092-8

  • 29.

    Bøtker-RasmussenIBagiPJørgensenJB. Is bladder outlet obstruction normal in elderly men without lower urinary tract symptoms?Neurourol Urodyn. (1999) 18:54551. 10.1002/(sici)1520-6777(1999)18:6%3C545::aid-nau2%3E3.0.co;2-1

  • 30.

    KojimaMOchiaiANayaYOkiharaKUkimuraOMikiT. Doppler resistive index in benign prostatic hyperplasia: correlation with ultrasonic appearance of the prostate and infravesical obstruction. Eur Urol. (2000) 37:43642. 10.1159/000020165

  • 31.

    SteeleGSSullivanMPSleepDJYallaSV. Combination of symptom score, flow rate and prostate volume for predicting bladder outflow obstruction in men with lower urinary tract symptoms. J Urol. (2000) 164:3448. 10.1016/S0022-5347(05)67356-9

  • 32.

    SullivanMPYallaSV. Penile urethral compression-release maneuver as a non-invasive screening test for diagnosing prostatic obstruction. Neurourol Urodyn. (2000) 19:65769. 10.1002/1520-6777(2000)19:6%3C657::aid-nau3%3E3.0.co;2-r

  • 33.

    OelkeMHöfnerKWieseBGrünewaldVJonasU. Increase in detrusor wall thickness indicates bladder outlet obstruction (BOO) in men. World J Urol. (2002) 19:44352. 10.1007/s00345-001-0238-z

  • 34.

    WatanabeTMiyagawaI. New simple method of transabdominal ultrasound to assess the degree of benign prostatic obstruction: size and horizontal shape of the prostate. Int J Urol. (2002) 9(4):2049. 10.1046/j.1442-2042.2002.00450.x

  • 35.

    BelenkyAAbarbanelYCohenMYossepowitchOLivnePMBacharGN. Detrusor resistive index evaluated by Doppler ultrasonography as a potential indicator of bladder outlet obstruction. Urology. (2003) 62:64750. 10.1016/s0090-4295(03)00510-7

  • 36.

    ChiaSJHengCTChanSPFooKT. Correlation of intravesical prostatic protrusion with bladder outlet obstruction. BJU Int. (2003) 91:3714. 10.1046/j.1464-410x.2003.04088.x

  • 37.

    SalinasJVírsedaMArredondoF. Validity of cuff-uroflow as a diagnostic technique for bladder outlet obstruction in males. Scand J Urol Nephrol. (2003) 37:31621. 10.1080/00365590310001610

  • 38.

    AganovicD. The role of uroflowmetry in diagnosis of infravesical obstruction in the patients with benign prostatic enlargement. Med Arh. (2004) 58:10911. https://www.scopus.com/record/display.uri?eid=2-s2.0-2542477308/origin=inward

  • 39.

    HardingCKRobsonWDrinnanMJGriffithsCJRamsdenPDPickardRS. An automated penile compression release maneuver as a noninvasive test for diagnosis of bladder outlet obstruction. J Urol. (2004) 172:23125. 10.1097/01.ju.0000144027.75838.60

  • 40.

    GriffithsCJHardingCBlakeCMcIntoshSDrinnanMJRobsonWAet alA nomogram to classify men with lower urinary tract symptoms using urine flow and noninvasive measurement of bladder pressure. J Urol. (2005) 174:13236. 10.1097/01.ju.0000173637.07357.9e

  • 41.

    NoseHFooKTLimKBYokoyamaTOzawaHKumonH. Accuracy of two noninvasive methods of diagnosing bladder outlet obstruction using ultrasonography: intravesical prostatic protrusion and velocity-flow video urodynamics. Urology. (2005) 65:4937. 10.1016/j.urology.2004.10.014

  • 42.

    KesslerTMGerberRBurkhardFCStuderUEDanuserH. Ultrasound assessment of detrusor thickness in men-can it predict bladder outlet obstruction and replace pressure flow study?J Urol. (2006) 175:21703. 10.1016/S0022-5347(06)00316-8

  • 43.

    LimKBHoHFooKTWongMYFook-ChongS. Comparison of intravesical prostatic protrusion, prostate volume and serum prostatic-specific antigen in the evaluation of bladder outlet obstruction. Int J Urol. (2006) 13:150913. 10.1111/j.1442-2042.2006.01611.x

  • 44.

    OelkeMHöfnerKJonasURosetteJJUbbinkDTWijkstraH. Diagnostic accuracy of noninvasive tests to evaluate bladder outlet obstruction in men: detrusor wall thickness, uroflowmetry, postvoid residual urine, and prostate volume. Eur Urol. (2007) 52:82734. 10.1016/j.eururo.2006.12.023

  • 45.

    ReisLOBarreiroGCBaracatJPrudenteAD'AnconaCA. Intravesical protrusion of the prostate as a predictive method of bladder outlet obstruction. Int Braz J Urol. (2008) 34:62733. 10.1590/s1677-55382008000500012

  • 46.

    KuJHChoSYOhSJ. Residual fraction as a parameter to predict bladder outlet obstruction in men with lower urinary tract symptoms. Int J Urol. (2009) 16:73944. 10.1111/j.1442-2042.2009.02354.x

  • 47.

    FrancoGDe NunzioCLeonardoCTubaroACiccarielloMDe DominicisCet alUltrasound assessment of intravesical prostatic protrusion and detrusor wall thickness–new standards for noninvasive bladder outlet obstruction diagnosis?J Urol. (2010) 183:22704. 10.1016/j.juro.2010.02.019

  • 48.

    Abdel-AalAEl-KaramanyTAl-AdlAMAbdel-WahabOFaroukH. Assessment of noninvasive predictors of bladder outlet obstruction and acute urinary retention secondary to benign prostatic enlargement. Arab J Urol. (2011) 9:20914. 10.1016/j.aju.2011.09.003

  • 49.

    PascualEMPoloAMoralesGSotoARogelRGarcíaGet alUsefulness of bladder-prostate ultrasound in the diagnosis of obstruction/hyperactivity in males with BPH. Arch Esp Urol. (2011) 64:897903. https://www.scopus.com/record/display.uri?eid=2-s2.0-82155197316/origin=inward

  • 50.

    AganovicDHasanbegovicMPrcicAKulovacBHadziosmanovicO. Which is a better indicator of bladder outlet obstruction in patients with benign prostatic enlargement–intravesical protrusion of prostate or bladder wall thickness?Med Arch. (2012) 66:3248. 10.5455/medarh.2012.66.324-328

  • 51.

    AganovicDPrcicAHadziosmanovicOHasanbegovicM. Does the combination of intravesical prostatic protrusion and bladder outlet obstruction number increase test accuracy according to benign prostatic obstruction at the individual level?Acta Inform Med. (2012) 20:1606. 10.5455/aim.2012.20.160-166

  • 52.

    AldaqadossiHAElgamalSASaadM. The value of measuring the prostatic resistive index vs. pressure-flow studies in the diagnosis of bladder outlet obstruction caused by benign prostatic hyperplasia. Arab J Urol. (2012) 10:18691. 10.1016/j.aju.2011.12.011

  • 53.

    HossainAKAlamAKHabibAKRashidMMRahmanHIslamAKet alComparison between prostate volume and intravesical prostatic protrusion in detecting bladder outlet obstruction due to benign prostatic hyperplasia. Bangladesh Med Res Counc Bull. (2012) 38:147. 10.3329/bmrcb.v38i1.10446

  • 54.

    ZhangXLiGWeiXMoXHuLZhaYet alResistive index of prostate capsular arteries: a newly identified parameter to diagnose and assess bladder outlet obstruction in patients with benign prostatic hyperplasia. J Urol. (2012) 188:8817. 10.1016/j.juro.2012.04.114

  • 55.

    ElSaiedWMosharafaAElFayoumyHElghoniemyMZiadaAElghamrawyH. Detrusor wall thickness compared to other non-invasive methods in diagnosing men with bladder outlet obstruction: a prospective controlled study. Afr J Urol. (2013) 19:16064. 10.1016/j.afju.2013.03.003

  • 56.

    ShinSHKimJWKimJWOhMMMoon duG. Defining the degree of intravesical prostatic protrusion in association with bladder outlet obstruction. Korean J Urol. (2013) 54:36972. 10.4111/kju.2013.54.6.369

  • 57.

    BianchiDDi SantoAGazievGMianoRMuscoSVespasianiGet alCorrelation between penile cuff test and pressure-flow study in patients candidates for trans-urethral resection of prostate. BMC Urol. (2014) 14:103. 10.1186/1471-2490-14-103

  • 58.

    ZhangMFuSZhangYTangJZhouY. Elastic modulus of the prostate: a new non-invasive feature to diagnose bladder outlet obstruction in patients with benign prostatic hyperplasia. Ultrasound Med Biol. (2014) 40:140813. 10.1016/j.ultrasmedbio.2013.10.012

  • 59.

    KazemeyniSMOtrojEMehrabanDNaderiGHGhadiriAJafariM. The role of noninvasive penile cuff test in patients with bladder outlet obstruction. Korean J Urol. (2015) 56:7228. 10.4111/kju.2015.56.10.722

  • 60.

    MatulewiczRSHairstonJC. The urocuff test: a non-invasive alternative to pressure flow studies in adult males with lower urinary tract symptoms secondary to bladder outlet obstruction. Can J Urol. (2015) 22:7896901. https://www.scopus.com/record/display.uri?eid=2-s2.0-84939183162/origin=inward

  • 61.

    AhmedAFBedewiM. Can bladder and prostate sonomorphology be used for detecting bladder outlet obstruction in patients with symptomatic benign prostatic hyperplasia?Urology. (2016) 98:12631. 10.1016/j.urology.2016.08.033

  • 62.

    LeeALeeHJLimKBHuangHHHoHFooKT. Can intravesical prostatic protrusion predict bladder outlet obstruction even in men with good flow?Asian J Urol. (2016) 3:3943. 10.1016/j.ajur.2015.10.002

  • 63.

    SuzukiTOtsukaAOzonoS. Combination of intravesical prostatic protrusion and resistive index is useful to predict bladder outlet obstruction in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Int J Urol. (2016) 23:92933. 10.1111/iju.13188

  • 64.

    FaragFElbadryMSaberMBadawyAAHeesakkersJ. A novel algorithm for the non-invasive detection of bladder outlet obstruction in men with lower urinary tract symptoms. Arab J Urol. (2017) 15:1538. 10.1016/j.aju.2017.01.002

  • 65.

    KoKJSuhYSKimTHSungHHRyuGHLeeKS. Diagnosing bladder outlet obstruction using the penile cuff test in men with lower urinary tract symptoms. Neurourol Urodyn. (2017) 36:18849. 10.1002/nau.23203

  • 66.

    AganovicDKulovacBBajramovicSKesmerA. Penile compression release Index revisited: evaluation and comparison with other noninvasive tools in the prediction of bladder outlet obstruction in men with benign prostatic enlargement. Med Arch. (2019) 73:816. 10.5455/medarh.2019.73.81-86

  • 67.

    GargGSankhwarSNGoelAPandeySSharmaDPariharA. Evaluation of resistive index of the prostate and bladder sonomorphologic parameters as replacements for urodynamics to predict bladder outlet obstruction in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Low Urin Tract Symptoms. (2019) 11:1638. 10.1111/luts.12256

  • 68.

    ReddySVKShaikAB. Non-invasive evaluation of bladder outlet obstruction in benign prostatic hyperplasia: a clinical correlation study. Arab J Urol. (2019) 17:25964. 10.1080/2090598X.2019.1660071

  • 69.

    KimKSChoiYSBaeWJChoHJLeeJYHongSHet alComparison of penile cuff test and conventional urodynamic study prior to photoselective vaporization of prostate for benign prostate hyperplasia using a 120 W greenlight high performance system laser. J Clin Med. (2020) 9:1189. 10.3390/jcm9041189

  • 70.

    Al-MosawiHQAl-AridyHMHameedHG. Accuracy of intravesical prostate protrusion measured by trans-abdominal ultrasound in predicting bladder outlet obstruction. Int J Pharm Res. (2020) 12:1150. 10.31838/ijpr/2020.12.02.0170

  • 71.

    ParkJSuhJYooSChoMCSonH. Bladder wall thickness and detrusor wall thickness can help to predict the bladder outlet obstruction in men over the age of 70 years with symptomatic benign prostatic hyperplasia. Investig Clin Urol. (2020) 61:4917. 10.4111/icu.20190376

  • 72.

    WadieBS. How correlated is BOO with different objective parameters commonly used in evaluation of BPH: a prospective study. Int Urol Nephrol. (2021) 53:63540. 10.1007/s11255-020-02707-4

  • 73.

    GlasASLijmerJGPrinsMHBonselGJBossuytPM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. (2003) 56:112935. 10.1016/s0895-4356(03)00177-x

  • 74.

    PetittiDB. Approaches to heterogeneity in meta-analysis. Stat Med. (2001) 20:362533. 10.1002/sim.1091

Summary

Keywords

lower urinary tract symptoms, bladder outlet obstruction, non-invasive methods, diagnosis, meta-analysis

Citation

Cheng Y, Li T, Wu X, Ling Q, Rao K, Yuan X, Chen Z, Du G and Xu S (2022) The diagnostic value of non-invasive methods for diagnosing bladder outlet obstruction in men with lower urinary tract symptoms: A meta-analysis. Front. Surg. 9:986679. doi: 10.3389/fsurg.2022.986679

Received

05 July 2022

Accepted

05 September 2022

Published

20 September 2022

Volume

9 - 2022

Edited by

Petros Sountoulides, Aristotle University of Thessaloniki, Greece

Reviewed by

Mingxing Xie, Huazhong University of Science and Technology, China Bassem S. Wadie, Mansoura University, Egypt

Updates

Copyright

*Correspondence: Shengfei Xu

Specialty Section: This article was submitted to Genitourinary Surgery, a section of the journal Frontiers in Surgery

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics